天风证券发布研究报告称，维持 信达生物 ...

【解剖大盘】A股终于开盘，经过国庆的发酵，开盘即出现井喷。沪指高开10.13%，达到3674.4点，创业板指高开幅度高达18.44%。成交量首次突破三万亿，达到3.45万亿的历史巨量，上涨股票超5000只，市场呈现一片牛市欣欣向荣景象。而港股这边画风 ...

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Piper Sandler维持Acelyrin Inc (NASDAQ: SLRN)的"增持"评级和20.00美元的目标价。 该公司的立场是在预期2024年底或2025年初将获得lonigutamab的进一步Phase 1/2数据。 根据Acelyrin的管理团队表示，最近的ESOPRS数据突显了lonigutamab对甲状腺眼病 (TED)患者生活质量的显著影响。

4 It often occurs in people living with Graves' disease, but is a distinct disease that is caused by autoantibodies ...

“Fashion continues to turn against hatches so the 1 Series range has shrunk. But if a petrol auto suits you this is a fine car” It's one of the most satisfying compact hatches around. Much ...

相关研究结果发表在2024年9月9日的Cancer Cell期刊上，论文标题为“Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence”。 这项研究由路德维格 ...

With potential to have lonigutamab as a possible best-in-class anti-IGF-1R drug for TED, plus moving rapidly into phase 3 clinical testing, I believe that investors could benefit with any ...

VRDN-001 is also IV administered and is a monoclonal antibody, but also acts as a full antagonist of the IGF-1R signaling pathway. This should provide it with some advantages over Tepezza (above).